Mesenchymal-Stem-Cell-Based Drug Delivery Strategies for Biomedical Applications

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 1303

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Medykow 18 Street, 40-752 Katowice, Poland
Interests: molecular mechanisms; cell therapy; mesenchymal stem cells; tissue regeneration; drug delivery; epithelial-to-mesenchymal transition; microRNA; molecular cancer biology; metastasis; personalized medicine

E-Mail Website
Guest Editor
Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Medykow 18 Street, 40-752 Katowice, Poland
Interests: somatic cell reprogramming; gene/cell therapy; mesenchymal stem cells; induced pluripotent stem cells; molecular mechanisms; targeted delivery; chemical carriers; personalized medicine

E-Mail Website
Guest Editor
Department of Epidemiology, Medical University of Silesia, 40-055 Katowice, Poland
Interests: cardiology; myocardial infarction; tissue regeneration; cell therapy; mesenchymal stem cells; drug delivery system; nanoparticles/microparticles

Special Issue Information

Dear Colleagues,

Targeted delivery of drugs to specific organs and tissues is one of the most important directions in translational and clinical research. Among various drug-targeting approaches, cell-based delivery systems offer some unique strengths and have achieved exciting preclinical and clinical results. The use of mesenchymal stem cells as a targeted-delivery carrier is promising due to their ease of isolation, expansion, maintenance of their phenotype, and multilineage potential in vitro. Currently, MSC-based delivery represents a promising approach for several clinical applications, ranging from tissue repair to the treatment of pathologies such as diabetes, cardiovascular disease, neurological disorders, and cancer.

However, this approach still has many limitations in clinical translation, such as induction of immunogenicity, high costs, or variable effects. Moreover, the long-term effect of priming MSCs has not been evaluated yet. Further studies are needed to assess the impact of different priming approaches in clinic; the best sources for MSCs isolation; and the epigenetic modifications, immunogenicity, and tumorigenicity of primed and non-primed MSCs.

This Special Issue aims to present a collection of high-quality original articles and extensive reviews on MSC-based drug delivery systems for various clinical applications. Colleagues and authors are invited to submit papers that fall within the scope of this Special Issue.

Dr. Karolina Bajdak-Rusinek
Dr. Agnieszka Fus-Kujawa
Prof. Dr. Paweł Buszman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal stem cell
  • cell-based therapy
  • drug delivery system
  • nanoparticles/microparticles
  • cell migration
  • homing
  • MSC priming
  • biomedical applications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 1976 KiB  
Review
Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery
by Yasunari Matsuzaka and Ryu Yashiro
Pharmaceuticals 2024, 17(6), 707; https://doi.org/10.3390/ph17060707 - 30 May 2024
Cited by 1 | Viewed by 908
Abstract
Mesenchymal stem cells (MSCs) have emerged as a promising approach for drug delivery strategies because of their unique properties. These strategies include stem cell membrane-coated nanoparticles, stem cell-derived extracellular vesicles, immunomodulatory effects, stem cell-laden scaffolds, and scaffold-free stem cell sheets. MSCs offer advantages [...] Read more.
Mesenchymal stem cells (MSCs) have emerged as a promising approach for drug delivery strategies because of their unique properties. These strategies include stem cell membrane-coated nanoparticles, stem cell-derived extracellular vesicles, immunomodulatory effects, stem cell-laden scaffolds, and scaffold-free stem cell sheets. MSCs offer advantages such as low immunogenicity, homing ability, and tumor tropism, making them ideal for targeted drug delivery systems. Stem cell-derived extracellular vesicles have gained attention for their immune properties and tumor-homing abilities, presenting a potential solution for drug delivery challenges. The relationship between MSC-based drug delivery and the self-renewal and differentiation capabilities of MSCs lies in the potential of engineered MSCs to serve as effective carriers for therapeutic agents while maintaining their intrinsic properties. MSCs exhibit potent immunosuppressive functions in MSC-based drug delivery strategies. Stem cell-derived EVs have low immunogenicity and strong therapeutic potential for tissue repair and regeneration. Scaffold-free stem cell sheets represent a cutting-edge approach in regenerative medicine, offering a versatile platform for tissue engineering and regeneration across different medical specialties. MSCs have shown great potential for clinical applications in regenerative medicine because of their ability to differentiate into various cell types, secrete bioactive factors, and modulate immune responses. Researchers are exploring these innovative approaches to enhance drug delivery efficiency and effectiveness in treating various diseases. Full article
Show Figures

Graphical abstract

Back to TopTop